JP2017507918A - Hpvおよび関連する疾病のための免疫増強治療ワクチン - Google Patents
Hpvおよび関連する疾病のための免疫増強治療ワクチン Download PDFInfo
- Publication number
- JP2017507918A JP2017507918A JP2016546446A JP2016546446A JP2017507918A JP 2017507918 A JP2017507918 A JP 2017507918A JP 2016546446 A JP2016546446 A JP 2016546446A JP 2016546446 A JP2016546446 A JP 2016546446A JP 2017507918 A JP2017507918 A JP 2017507918A
- Authority
- JP
- Japan
- Prior art keywords
- recombinant
- vector
- hpv
- protein
- gene expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (15)
- ヒトパピローマウイルス(HPV)の5つの遺伝子と、免疫増強因子との融合抗原であって、HPV16型のE6およびE7タンパク質と、HPV18型のE6およびE7タンパク質と、免疫増強分子のアジュバントタンパク質と、を含む融合抗原。
- 1つ以上の変異点を有し、HPV16型のE6タンパク質の121番目の位置でグルタミン酸がグリシンで置換されており、122番目の位置でリシンがグリシンに置換されており、HPV16型のE7タンパク質の24番目の位置でシステインがグリシンに置換されており、26番目の位置でグルタミン酸がグリシンに置換されており、HPV18型のE6タンパク質の116番目の位置でグルタミン酸がグリシンに置換されており、117番目の位置でリシンがグリシンに置換されており、HPV18型のE7タンパク質の27番目の位置でシステインがグリシンに置換されており、29番目の位置でグルタミン酸がグリシンに置換されていることを特徴とする請求項1に記載の融合抗原。
- 前記免疫増強因子のアジュバントタンパク質は、原核生物または哺乳類由来の熱ショックタンパク質であって、好ましくは、結核菌由来の熱ショックタンパク質であることを特徴とする請求項1または2に記載の融合抗原。
- 請求項1から3のいずれか1項に記載の融合抗原を発現させるための組換え遺伝子発現ベクター。
- 請求項1から3のいずれか1項に記載の融合抗原を発現させるための発現カセット、および免疫刺激剤を発現させるための発現カセットを運搬することを特徴とする請求項4に記載の組換え遺伝子発現ベクター。
- 前記免疫刺激剤は、顆粒球・マクロファージコロニー刺激因子(GM−CSF)、またはインターロイキン、またはインターフェロン、またはケモカインであって、好ましくは顆粒球・マクロファージコロニー刺激因子(GM−CSF)であることを特徴とする請求項5に記載の組換え遺伝子発現ベクター。
- SEQ ID No.3で表現されるヌクレオチド配列を有するDNAフラグメントを運搬することを特徴とする請求項4から6のいずれか1項に記載の組換え遺伝子発現ベクター。
- 組換えアデノウイルスベクター、または組換えアデノ随伴ウイルスベクター、または組換えレトロウイルスベクター、または組換えレンチウイルスベクター、または組換えヘルペスウイルスベクター、または組換えワクシニアベクター、または組換えセンダイウイルスベクターであることを特徴とする請求項4から6のいずれか1項に記載の組換え遺伝子発現ベクター。
- 裸DNAベクター、ナノ粒子、ポリマー、リポソームよりなる群から選択される非ウイルスベクターであることを特徴とする請求項4から6のいずれか1項に記載の組換え遺伝子発現ベクター。
- 治療効果を有する量の請求項1から3のいずれか1項に記載の融合抗原、または治療効果を有する量の請求項4から9のいずれか1項に記載の組換え遺伝子発現ベクターを含む、HPV感染に誘起される疾病を治療するための医薬製剤。
- 治療効果を有する量の請求項1から3のいずれか1項に記載の融合抗原と、免疫刺激剤とを含むことを特徴とする請求項10に記載の医薬製剤。
- 前記免疫刺激剤は、顆粒球・マクロファージコロニー刺激因子(GM−CSF)、またはインターロイキン、またはインターフェロン、またはケモカインであって、好ましくは顆粒球・マクロファージコロニー刺激因子(GM−CSF)であることを特徴とする請求項11に記載の医薬製剤。
- 請求項4から9のいずれか1項に記載の組換え遺伝子発現ベクターを運搬することを特徴とする組換えアデノウイルス。
- HPV感染によって誘起される疾病を治療するための医薬品の製造に用いる、請求項1から3のいずれか1項に記載の融合抗原、または請求項4から9のいずれか1項に記載の組換え遺伝子発現ベクター、または請求項10から12のいずれか1項に記載の医薬製剤、または請求項13に記載のアデノウイルスの使用法用。
- 前記HPV感染によって誘起される疾病は、HPV慢性感染に関連する疾病であり、好ましくは、子宮頸癌、陰茎癌、肛門癌、咽頭癌、口腔癌、頭および首の癌、子宮頸部前癌病変、子宮頸部過形成であることを特徴とする請求項14に記載の使用方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410017909.8A CN103772508B (zh) | 2014-01-15 | 2014-01-15 | 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗 |
CN201410017909.8 | 2014-01-15 | ||
PCT/CN2015/070789 WO2015106697A1 (zh) | 2014-01-15 | 2015-01-15 | 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017507918A true JP2017507918A (ja) | 2017-03-23 |
JP6945301B2 JP6945301B2 (ja) | 2021-10-06 |
Family
ID=50565318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016546446A Active JP6945301B2 (ja) | 2014-01-15 | 2015-01-15 | Hpvおよび関連する疾病のための免疫増強治療ワクチン |
Country Status (11)
Country | Link |
---|---|
US (1) | US10071150B2 (ja) |
EP (1) | EP3095798B1 (ja) |
JP (1) | JP6945301B2 (ja) |
KR (1) | KR102351555B1 (ja) |
CN (1) | CN103772508B (ja) |
AU (1) | AU2015207548B2 (ja) |
CA (1) | CA2937023A1 (ja) |
DK (1) | DK3095798T3 (ja) |
ES (1) | ES2848064T3 (ja) |
MX (1) | MX2016009189A (ja) |
WO (1) | WO2015106697A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020251014A1 (ja) * | 2019-06-14 | 2020-12-17 | 国立研究開発法人理化学研究所 | 免疫系を賦活化する細胞および当該細胞を含む医薬組成物 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103772508B (zh) | 2014-01-15 | 2017-05-10 | 深圳泰来生物医药有限公司 | 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗 |
US20170266273A1 (en) * | 2014-08-01 | 2017-09-21 | Guangdong Tophealth Biotechnology Co., Ltd. | Recombinant adeno-associated virus vectors carrying the mutant hpv- 16 e7 antigen gene, construction method and application thereof |
CN105801704B (zh) * | 2014-12-31 | 2020-06-02 | 艾托金生物医药(苏州)有限公司 | 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用 |
US10561723B2 (en) | 2015-07-21 | 2020-02-18 | Theodore C. Marbley | Treatment and prevention of anal conditions |
WO2017096432A1 (en) * | 2015-12-09 | 2017-06-15 | Admedus Vaccines Pty Ltd | Immunomodulating composition for treatment |
CN106754758A (zh) * | 2016-12-29 | 2017-05-31 | 汕头大学医学院 | 一种含细胞因子佐剂的重组肠道病毒表型混合系统的构建方法及其应用 |
CN106632694B (zh) * | 2017-01-24 | 2021-02-12 | 南京益康生物医药有限公司 | 一种重组蛋白及药物组合物与应用 |
CN108567977B (zh) * | 2017-03-13 | 2022-04-12 | 复旦大学 | 一种免疫增强剂、免疫治疗药物组合物及其制备与用途 |
WO2018166298A1 (en) * | 2017-03-13 | 2018-09-20 | Fudan University | Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use |
CN106963945A (zh) * | 2017-03-27 | 2017-07-21 | 山东兴瑞生物科技有限公司 | 一种加强型人乳头瘤病毒hpv‑16/18的二价dc疫苗 |
CA3058938A1 (en) * | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
CN108484776B (zh) * | 2018-03-19 | 2019-11-05 | 首都医科大学附属北京朝阳医院 | 一种融合蛋白、制备方法及其应用 |
JP2022535356A (ja) * | 2019-05-31 | 2022-08-08 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | 多形性神経膠芽腫を処置するための免疫療法組成物 |
CN110734477A (zh) * | 2019-11-18 | 2020-01-31 | 维塔恩(广州)医药有限公司 | 乳头瘤病毒相关抗原短肽及其应用 |
CN111088286B (zh) * | 2020-01-16 | 2021-10-22 | 广东拓谱康生物科技有限公司 | 一种重组腺相关病毒载体的构建和制备及其应用价值 |
CN114099662A (zh) * | 2021-10-27 | 2022-03-01 | 山西协策企业管理咨询有限公司 | 一种单核细胞负载e6e7融合蛋白的疫苗组合物及其制备方法与应用 |
CN114134165B (zh) * | 2022-01-27 | 2022-04-29 | 北京循生生物医学研究有限公司 | 一种新型hpv治疗性核酸疫苗 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513986A (ja) * | 1997-08-22 | 2001-09-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
US7201908B2 (en) * | 2001-03-23 | 2007-04-10 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Modified HPV E6 and E7 genes and proteins useful for vaccination |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
US6734173B1 (en) * | 1999-10-20 | 2004-05-11 | Johns Hopkins University | HSP DNA vaccines |
RU2229307C1 (ru) * | 2002-10-22 | 2004-05-27 | ООО "Фирма"БиоМедИнвест" | Композиция рекомбинантных белков, способ получения такой композиции, фармацевтический набор реагентов для иммунотерапии и профилактической вакцинации опухолевых заболеваний аногенитальной сферы, способ иммунотерапии и профилактической вакцинации на его основе |
CN1299769C (zh) * | 2005-01-31 | 2007-02-14 | 中国医学科学院肿瘤医院肿瘤研究所 | 人乳头瘤病毒和热休克蛋白重组蛋白疫苗及其用途 |
CN1900118A (zh) * | 2005-07-21 | 2007-01-24 | 张伟 | 包含热休克蛋白和hpv16z蛋白抗原的无佐剂治疗性蛋白疫苗 |
EP2010572B1 (en) * | 2006-04-19 | 2013-10-23 | POSTECH Academy-Industry Foundation | Fusion proteins comprising hpv polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer |
WO2008046251A1 (fr) * | 2006-10-19 | 2008-04-24 | Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. | Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées |
WO2009111088A2 (en) * | 2008-01-02 | 2009-09-11 | The Johns Hopkins University | Antitumor immunization by liposomal delivery of vaccine to the spleen |
CN102002105B (zh) * | 2009-09-03 | 2013-01-23 | 中国疾病预防控制中心病毒病预防控制所 | Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途 |
CN102228698B (zh) * | 2011-06-28 | 2013-12-18 | 广西医科大学附属肿瘤医院 | Hpv58型治疗性复合基因疫苗及其构建方法 |
CN103772508B (zh) | 2014-01-15 | 2017-05-10 | 深圳泰来生物医药有限公司 | 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗 |
-
2014
- 2014-01-15 CN CN201410017909.8A patent/CN103772508B/zh active Active
-
2015
- 2015-01-15 US US15/111,758 patent/US10071150B2/en active Active
- 2015-01-15 MX MX2016009189A patent/MX2016009189A/es unknown
- 2015-01-15 AU AU2015207548A patent/AU2015207548B2/en active Active
- 2015-01-15 KR KR1020167020050A patent/KR102351555B1/ko active IP Right Grant
- 2015-01-15 WO PCT/CN2015/070789 patent/WO2015106697A1/zh active Application Filing
- 2015-01-15 EP EP15736908.3A patent/EP3095798B1/en active Active
- 2015-01-15 ES ES15736908T patent/ES2848064T3/es active Active
- 2015-01-15 JP JP2016546446A patent/JP6945301B2/ja active Active
- 2015-01-15 DK DK15736908.3T patent/DK3095798T3/da active
- 2015-01-15 CA CA2937023A patent/CA2937023A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513986A (ja) * | 1997-08-22 | 2001-09-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
US7201908B2 (en) * | 2001-03-23 | 2007-04-10 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Modified HPV E6 and E7 genes and proteins useful for vaccination |
Non-Patent Citations (5)
Title |
---|
BOURSNELL, M.E.G. ET AL., VACCINE, vol. Vol.14, No.16(1996), JPN6018029289, pages 1485 - 1494, ISSN: 0004120992 * |
CROOK T. ET AL., CELL, vol. vol.67 (1991), JPN6019036944, pages 547 - 556, ISSN: 0004120996 * |
HUANG, CHIA-YEN, ET AL, GYNECOLOGIC ONCOLOGY, vol. Vol.107(2007), JPN6018029295, pages 404 - 412, ISSN: 0004120994 * |
LIN K. ET AL., IMMUNOLOGIC RESARCH, vol. Vol. 47, No.1-3(2010), JPN6018029292, pages 86 - 112, ISSN: 0004120993 * |
REALI, E. ET AL., VACCINE, vol. vol.23(2005), JPN6018029298, pages 2909 - 2921, ISSN: 0004120995 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020251014A1 (ja) * | 2019-06-14 | 2020-12-17 | 国立研究開発法人理化学研究所 | 免疫系を賦活化する細胞および当該細胞を含む医薬組成物 |
JP2020202750A (ja) * | 2019-06-14 | 2020-12-24 | 国立研究開発法人理化学研究所 | 免疫系を賦活化する細胞および当該細胞を含む医薬組成物 |
JP7125760B2 (ja) | 2019-06-14 | 2022-08-25 | 国立研究開発法人理化学研究所 | 免疫系を賦活化する細胞および当該細胞を含む医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
AU2015207548A2 (en) | 2016-07-21 |
WO2015106697A1 (zh) | 2015-07-23 |
EP3095798B1 (en) | 2020-12-16 |
DK3095798T3 (da) | 2021-01-11 |
EP3095798A4 (en) | 2017-11-22 |
EP3095798A1 (en) | 2016-11-23 |
CA2937023A1 (en) | 2015-07-23 |
JP6945301B2 (ja) | 2021-10-06 |
MX2016009189A (es) | 2016-11-08 |
US20160324952A1 (en) | 2016-11-10 |
AU2015207548B2 (en) | 2019-11-21 |
KR102351555B1 (ko) | 2022-01-14 |
CN103772508B (zh) | 2017-05-10 |
CN103772508A (zh) | 2014-05-07 |
ES2848064T3 (es) | 2021-08-05 |
KR20160106082A (ko) | 2016-09-09 |
US10071150B2 (en) | 2018-09-11 |
AU2015207548A1 (en) | 2016-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6945301B2 (ja) | Hpvおよび関連する疾病のための免疫増強治療ワクチン | |
Su et al. | Immunotherapy for cervical cancer: Research status and clinical potential | |
ES2759785T3 (es) | Adenovirus que expresan antígenos oncógenos heterólogos | |
Berger et al. | Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma | |
CA2825470A1 (en) | Cyaa-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses | |
Martin Caballero et al. | Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7–dependent tumors | |
JP2022046617A (ja) | 異種ポリペプチドを含むCyaAベースのキメラタンパク質及び免疫応答の誘導におけるその使用 | |
WO2003031602A1 (fr) | Micro-organismes oncolytiques exprimant les proteines hsp, et leurs utilisations | |
Mohit et al. | Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections | |
KR101810840B1 (ko) | 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp) | |
US20170072034A1 (en) | Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase) | |
Daemi et al. | Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model | |
WO2020024982A1 (zh) | 一种基于减毒李斯特菌激活的抗原提呈细胞的肿瘤免疫治疗组合物、制备方法和应用 | |
US8053421B2 (en) | DNA vaccines against tumor growth and methods of use thereof | |
WO2023023940A1 (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
EP2601968A1 (en) | HPV derived polynucleic acids for therapy | |
EP2335730A1 (en) | Fusion polypeptides and their use for prevention and treatment of cancer | |
JP2016028025A (ja) | がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp) | |
Wei et al. | Interleukin-12 gene adjuvant increases the immunogenicity of virus-like particles of human papillomavirus type 16 regional variant strain | |
US9566319B2 (en) | p16INK4a derived peptides for prophylaxis and therapy of HPV-associated tumors and other p16INK4a expressing tumors | |
EP2573105A1 (en) | P16 inka4a derived peptides for prophylaxis and therapy of HPV-associated tumors and other p16 ink4a expressing tumors | |
JP2014118361A (ja) | がんの予防及び治療のためのmsi特異的なフレームシフトペプチド(fsp) | |
WO2021087851A1 (zh) | 一种重组病毒载体、包含其的免疫组合物以及用途 | |
Yu | a Dna vaccine encoding mutated hPV58 me6e7-Fc-gPi fusion antigen and gM-csF and B7. | |
TW202228769A (zh) | 用於人類乳突病毒的dna疫苗及其使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170907 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181025 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190319 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20190405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190527 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190719 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190719 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20190719 |
|
C12 | Written invitation by the commissioner to file intermediate amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C12 Effective date: 20190731 |
|
C272 | Notice of ex officio correction |
Free format text: JAPANESE INTERMEDIATE CODE: C272 Effective date: 20190731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190807 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190808 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20190820 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20190927 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20191001 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20200414 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20201201 |
|
C28A | Non-patent document cited |
Free format text: JAPANESE INTERMEDIATE CODE: C2838 Effective date: 20201201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210330 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210413 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20210713 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20210817 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20210817 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210914 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6945301 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |